Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Imunon ( (IMNN) ) is now available.
Imunon, Inc. has faced challenges with its Nasdaq listing due to non-compliance with the minimum bid price and stockholders’ equity requirements. On May 28, 2025, the company received a delisting determination letter, but a hearing panel granted an exception on July 11, 2025, allowing time to regain compliance. The potential delisting could impact stock trading and capital raising. Additionally, at the 2025 Annual Meeting on July 11, 2025, stockholders approved an amendment to the 2018 Stock Incentive Plan, increasing the share limit by 2,000,000 shares.
The most recent analyst rating on (IMNN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Imunon stock, see the IMNN Stock Forecast page.
Spark’s Take on IMNN Stock
According to Spark, TipRanks’ AI Analyst, IMNN is a Neutral.
Imunon’s financial instability, characterized by negative revenue and cash flow metrics, significantly impacts its overall stock score. Technical indicators suggest caution, with bearish trends and lack of momentum. Though the recent earnings call highlights promising clinical progress, concerns about cash runway and funding remain. Valuation metrics further reflect the stock’s risky profile, with a negative P/E ratio and no dividend yield.
To see Spark’s full report on IMNN stock, click here.
More about Imunon
Average Trading Volume: 11,783,880
Technical Sentiment Signal: Sell
Current Market Cap: $12.3M
See more data about IMNN stock on TipRanks’ Stock Analysis page.